When compared to other medical devices or instruments, biosensors are undergoing rapid growth in the industry. The reason behind its proliferation is that it gives researchers and companies exciting challenges to overcome. The principle behind present day industrial sensors, as well as new technologies, is under a process of constant experimentation and corresponding acclimatization in order to develop biosensors that are more effective. As the whole concept of biosensors has basic principles of science such as physics, chemistry and biology as foundations, there are a wide range of factors, which one can manipulate to develop a novel and more efficient sensor or technology platform.
Frost & Sullivan finds that Biosensor in Medical Diagnostics provides in-depth information about the various commercial diagnostic products and biosensing techniques available in the market today and those on the verge of commercialization.
“The number of people requiring medical attention is increasing primarily due to population explosion and also because people are succumbing to variegated ailments due to unhealthy day–to–day practices or occupational hazards,” says Frost & Sullivan Research Analyst Abhishek Dutta. “Individuals have started attributing more importance to health, especially with diseases such as diabetes, and the need for using biosensors for constantly sensing or monitoring blood glucose levels as well as other physiological factors has increased significantly.”
Nanotechnology has revolutionized the field of biosensors with increasing development of new concepts. There is increased investment in the development of nanobiosensors, as it proves to be a much-demanded technology once it hits the commercial stage. However, nanosensors need to undergo enormous developments to target issues such as biocompatibility, controlling a nanoswarm in its environment, and the capability to be replaced in case of defects.
Numerous biosensors are still in the stages of animal testing. Though there are positive results in animals, only a few ongoing human trials have shown some success. Commercially available implantable devices suiting user needs may be years away from approval for worldwide availability. Success or failure at the human clinical trials decides the future market potential of biosensors.
“Developing biosensors would involve tremendous costs as their developments have foundations in the use of other emerging technologies such as microcircuitry, nanomaterials, and others,” notes Dutta. “In addition, regulatory controls established by the Food Drug Administration(FDA) is the single most important factor between patient safety and technological developments. In the absence of these rules there will be nothing to control the quality, efficacy, and biocompatibility of biosensors from the patient or end-user perspective.”
The technology and its users are mainly looking forward to implantable, yet completely automated and intelligent sensing platforms or sensors, which render in maximum implantable time-period for patients. The automation should be such that the performance of sensing and diagnosis is without disrupting the patients’ normal lifestyle.
Biosensor in Medical Diagnostics is part of the Technical Insights, Healthcare Subscription and aims at increasing the market and product awareness for key industry participants in this field, aiding research and development of these medical sensors. This study also hopes to increase the awareness among the medical community and patients. By examining the key technologies utilized in this space such as non-invasive sensors, invasive devices, diagnostic test kits, and medical devices, this study provides an in-depth analysis of this industry.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.